Robert M. Rifkin
0000-0003-3141-1518
Publication & Citation Trends
Publications
0 total
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
Cited by 8
Semantic Scholar
Patient-reported outcomes and actigraphy following in-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in newly diagnosed multiple myeloma (NDMM): Subgroup analysis of US MM-6 by race/ethnicity, renal function, and area income
Cited by 0
Semantic Scholar
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial.
Cited by 1
Semantic Scholar
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.
Cited by 7
Semantic Scholar
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Cited by 107
Semantic Scholar
P-175 Real-World Minimal Residual Disease Testing Patterns: Findings From the Connect® MM Registry
Cited by 0
Semantic Scholar
OPTec: A phase 2 study to evaluate outpatient (OP) step-up administration of teclistamab (Tec), a BCMA-targeting bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Cited by 4
Semantic Scholar
The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry.
Cited by 1
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(189)
Protein Degradation and Inhibitors
(98)
Cancer Treatment and Pharmacology
(58)
Peptidase Inhibition and Analysis
(41)
Chronic Lymphocytic Leukemia Research
(30)
Affiliations
Translational Genomics Research Institute
Dartmouth–Hitchcock Medical Center
BC Cancer Agency
Cleveland Clinic
McKesson (United States)